Oncolytics says FDA opens a possible accelerated-approval route for pelareorep in RAS-mutant colorectal cancer
FDA written feedback supports a potential pivotal expansion of REO 033 using response rate and duration as an accelerated-approval strategy, but Oncolytics must first generate supportive randomized Part A data.